siltuximab at a glance
Medicine class
Interleukin‑6 inhibitor and monoclonal antibody
Licensed use
Multicentric Castleman disease in eligible adults who are HIV-negative and HHV‑8-negative
Administration
Given by intravenous infusion by qualified healthcare professionals
Key checks
Blood counts, infection, liver function and blood lipids require monitoring
What is siltuximab used for?
The selected product is licensed for:
Treatment of adults with multicentric Castleman disease who are HIV-negative and HHV‑8-negative.
How does siltuximab work?
Siltuximab binds soluble interleukin‑6 and prevents it activating its receptors. This reduces IL‑6-driven inflammation, acute-phase responses and abnormal lymph-node cell activity associated with multicentric Castleman disease.
siltuximab preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 100 mg, 400 mg
How to take siltuximab
Siltuximab is not taken by mouth. Hospital staff reconstitute and dilute the powder before giving it into a vein under medical supervision.
Attend the arranged infusion appointment.
Tell the team about infection symptoms, recent vaccinations and all other medicines before treatment.
Staff monitor for infusion reactions during administration.
siltuximab side effects
Common or expected effects
- Respiratory or urinary infections
- Itching, rash or eczema
- Headache or dizziness
- Nausea, vomiting, diarrhoea, constipation or abdominal discomfort
- Joint or limb pain
- Mouth ulcers or sore throat
- Swelling, raised blood pressure or weight gain
- Changes in blood counts, kidney tests, cholesterol, triglycerides or uric acid
Get urgent medical advice
- Severe allergic or infusion reaction, including breathing difficulty, wheezing, marked dizziness or swelling
- Serious infection, including pneumonia or sepsis; fever and inflammatory markers may be suppressed
- Worsening severe abdominal pain with nausea, fever or altered bowel habits, which may suggest gastrointestinal perforation
siltuximab in pregnancy
Human pregnancy data are unavailable, and siltuximab is not recommended during pregnancy unless the specialist judges that the benefit clearly outweighs the risk. Effective contraception is required during treatment and for three months afterwards. Because it can cross the placenta, the infant’s vaccination plan may need specialist review.
siltuximab while breastfeeding
It is unknown whether siltuximab passes into human milk, and risk to a breastfed infant cannot be excluded. The specialist and parent should decide whether to stop breastfeeding or avoid siltuximab after considering the benefits of each.
siltuximab interactions
Formal interaction studies have not been performed. Blocking IL‑6 may restore liver-enzyme activity and alter the handling of some medicines.
Warfarin
Its anticoagulant effect may change when siltuximab is started or stopped, so closer monitoring may be required.
Ciclosporin or theophylline
Blood concentrations may change; concentration monitoring and adjustment by the prescriber may be needed.
Oral contraceptives and other sensitive CYP3A4 substrates
Effectiveness could decrease, so the prescriber should review whether additional precautions are appropriate.
Common questions about siltuximab
Answers are fully visible for fast scanning and source review.
What disease is siltuximab licensed to treat?
It is licensed for adults with multicentric Castleman disease who are HIV-negative and HHV‑8-negative.
Is siltuximab chemotherapy?
It is a targeted monoclonal antibody and interleukin‑6 inhibitor rather than conventional cytotoxic chemotherapy.
Does siltuximab cure multicentric Castleman disease?
It is used to control IL‑6-driven disease activity and symptoms; it is not described as a cure.
Is siltuximab a tablet or an infusion?
It is an intravenous infusion prepared and given by healthcare professionals.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.